BRANFORD, Conn., Nov. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on
oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced
today that updated preliminary clinical trial results from the Phase II
study of belinostat for T-cell lymphomas, and new preclinical data
evaluating belinostat on pediatric leukemia cell lines, will be presented
at the 2007 American Society of Hematology (ASH) 49th Annual Meeting in
Atlanta, GA, on Monday, December 10, 2007.
The presentation details are as follows:
Title: Belinostat (PXD101) in Patients with Recurrent or Refractory
Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase
Date/Time: Monday, December 10, 2007, 5:00 - 7:00 PM EST
Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models-
Diffuse Large Cell Lymphoma and T-Cell Lymphoma
Poster board: 672-II
Title: Investigation of the Efficacy of PXD101 (Belinostat) on
Primary Leukaemic Cells and Cell Lines as a Novel Agent for
Childhood Acute Lymphoblastic Leukaemia (ALL)
Date/Time: Monday, December 10, 2007, 5:00 - 7:00 PM EST
Session: Acute Lymphocytic Leukemia: Biology and Pathophysiology
Poster board: 12-III
These abstracts are currently available online at http://www.abstracts2view.com/hem07. Following their presentation on December 10, 2007, reprints of the posters will be made available on CuraGen's website at http://www.curagen.com or by emailing firstname.lastname@example.org.
Belinostat is a small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid tumors and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid, azacitidine, idarubicin and Velcade(R) (bortezomib) for Injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti- cancer agents.
Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for cutaneous and peripheral T-cell lymphomas, B-cell lymphomas, AML, mesothelioma, soft tissue sarcoma, MDS, and liver, colorectal, and ovarian cancers, either alone or in combination with anti- cancer therapies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI will sponsor several clinical trials to investigate belinostat for the treatment of various cancers, both as a single-agent and in combination chemotherapy regimens. In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its anti-tumor activity and to provide supporting information for clinical trials.
CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including the histone deacetylase inhibitor, belinostat, and the antibody-drug conjugate, CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with subsidiaries in US, Switzerland, Germany and the UK, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FASligand and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and nine drugs (both small molecules and protein based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene(TM)/Totect(TM) was approved by EMEA in 2006 and the FDA in 2007 and is TopoTarget's first product on the market. For more information, please refer to http://www.topotarget.com.
Statements in this press release regarding CuraGen's belinostat
development program, including the presentation of updated preliminary
Phase II clinical trial results and new preclinical results at the ASH 49th
Annual Meeting may constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by terminology such as "anticipate,"
"believe," "could," "could increase the likelihood," "estimate," "expect,"
"intend," "is planned," "may," "should," "will," "will enable," "would be
expected," "look forward," "may provide," "would" or similar terms,
variations of such terms or the negative of those terms. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors including the risk that any one or more of CuraGen's drug
development programs will not proceed as planned for technical, scientific
or commercial reasons or due to patient enrollment issues or based on new
information from nonclinical or clinical studies or from other sources, the
success of competing products and technologies, CuraGen's stage of
development as a biopharmaceutical company, government regulation and
healthcare reform, technological uncertainty and product development risks,
product liability exposure, uncertainty of additional funding, CuraGen's
history of incurring losses and the uncertainty of achieving profitability,
reliance on research collaborations and strategic alliances, competition,
patent infringement claims against CuraGen's products, processes and
technologies, CuraGen's ability to protect its patents and proprietary
rights and uncertainties relating to commercialization rights, as well as
those risks, uncertainties and factors referred to in the Company's
Quarterly Report on Form 10-Q for the quarter ended September 30, 2007,
filed with the Securities and Exchange Commission under the section "Risk
Factors," as well as other documents that may be filed by CuraGen from time
to time with the Securities and Exchange Commission. As a result of such
risks, uncertainties and factors, the Company's actual results may differ
materially from any future results, performance or achievements discussed
in or implied by the forward-looking statements contained herein. CuraGen
is providing the information in this press release as of this date and
assumes no obligations to update the information included in this press
release or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Glenn Schulman, Pharm.D.
Director of Investor Relations
|SOURCE CuraGen Corporation|
Copyright©2007 PR Newswire.
All rights reserved